Myriad Genetics stock hits 52-week low at $12.16 amid market challenges
Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...
manilatimes8h
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and ...
Hosted on MSN1d
NCCN Publishes Vital Patient Resource on Genetic Testing for Hereditary Cancers
The National Comprehensive Cancer Network® (NCCN®) has released a new resource aimed at helping individuals understand genetic testing and counseling for hereditary cancers. This patient-friendly ...
Leerink Partners Sticks to Their Hold Rating for Myriad Genetics (MYGN)
In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...
Myriad Genetics announces hereditary cancer risk assessment study published
Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, ...